Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
47 hedge funds and large institutions have $201M invested in Dicerna Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
38% more capital invested
Capital invested by funds: $146M → $201M (+$55.1M)
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
18% more funds holding
Funds holding: 40 → 47 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.31M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.04M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.8M |
| 5 |
TA
Teachers Advisors
New York
|
+$564K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$30.9M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$7.14M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.71M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.32M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$871K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
51
SSI Investment Management
Los Angeles,
California
| – | -$192K | -15,110 | Closed |
|
|
CS
52
Credit Suisse
Zurich,
Switzerland
| – | -$159K | -12,536 | Closed |
|
53
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$141K | -12,245 | -100% |
|
|
SSG
54
Summit Securities Group
New York
| – | -$67K | -5,263 | Closed |
|
55
BNP Paribas Financial Markets
Paris,
France
| – | -$2.13K | -167 | Closed |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$23 | +2 | New |
|
DRNA Hedge Fund Activity: Q4 2014 in Review
47 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2014, worth a combined $201M — up 38% from $146M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DRNA positions and 9 closed out — a net gain of 8 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $17.5M. The largest seller was Deerfield Management, exiting entirely with an estimated $30.9M sold.
- 47 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2014, up from 40 in Q3 2014.
- Funds reported $201M of Dicerna Pharmaceuticals, Inc. stock for Q4 2014, up 38% quarter-over-quarter.
- 17 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2014 and 9 closed out, a net change of +8 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2014 was Wellington Management Group, an estimated $17.5M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2014 was Deerfield Management, an estimated $30.9M sold.
Based on aggregated 13F filings for Q4 2014.